CHAPEL HILL, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 25th European Congress of Clinical Microbiology (ECCMID), in Copenhagen, Denmark, April 25-28 and the 2015 Pediatric Academic Societies (PAS) Annual Meeting in San Diego, April 25-28. Additional abstracts of solithromycin study results are being submitted for presentation at appropriate medical meetings.
Presentations at ECCMID:
- Results of a Global Phase 3 Trial Comparing Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community Acquired Bacterial Pneumonia (CABP) in Adults – LBOS Late breaker: results from latest clinical trial, April 28, oral presentation by David Oldach at 11:54 a.m. CET in Hall E. An abstract for the late breaker presentation is available on the ECCMID meeting website.
- Solithromycin, a 4th Generation Macrolide and the 1st Fluoroketolide, Does Not Prolong the QTc Interval: Results of a Definitive QT Study – E-poster, April 25 (all day).
- In vitro susceptibility of S. pneumoniae to solithromycin (SOL) in Belgian and German collections with an elevated percentage of isolates resistant to macrolides and fluoroquinolones – E-poster, April 25 (all day).
- Efficacy of Solithromycin against Enterococcus faecalis in a Neutropenic Mouse Thigh Abscess Model – E-poster, April 25 (all day).
- Activity of Fusidic acid (FUS) alone or in combination with Daptomycin (DAP), Vancomycin (VAN), or Linezolid (LDZ) in an in vitro model of Staphylococcus aureus Biofilm – E-Poster, April 25 (all day).
- Rifampin (RIF) significantly reduces plasma concentrations of fusidic acid (FA) when used in combination for treatment of prosthetic joint infection (PJI) – Poster, Poster Area, April 28 at 12:30 p.m. CET. An abstract is available using the link Rifampin.
Presentation at PAS:
- Pharmacokinetics and Safety of Solithromycin in Adolescents with Suspected or Confirmed Bacterial Infection – Poster, Exhibit Hall EFG, April 25 at 1:00 p.m. PDT. This work was funded by BARDA (Biomedical Advanced Research and Development Authority).
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin has also entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.